Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Walker Crips secures £5m lifeline after swinging to full-year loss

(Sharecast News) - Investments, financial planning and pensions group Walker Crips has decided not to issue a dividend to shareholders after swinging to a big loss in the year to 31 March, as it announced a new £5m working capital loan. In a statement to the market late on Thursday, the company said that, due to "a number of historic challenges", the company had to fund substantial investments in legal and consulting services, as well as the recruitment of additional compliance personnel.

Meanwhile, attracting and retaining essential risk and compliance staff meant "considerable" salary increases were necessary.

As a result, Walker Crips reported a loss before tax of £3.28m for the year, compared with a profit of £0.39m the year before, with revenues falling 0.7% to £31.35m.

Chair Jo Welman, who joined the company on the first day of the new financial year, is now spearheading a "comprehensive review" of the business, including its operating structure, risk management processes, client servicing capabilities, and business culture.

"This will encompass an assessment of our strategic options to strengthen the balance sheet, as well as a wider review of our group's culture, with a focus on fostering greater alignment around shared objectives and enhancing our collective responsibility for both individual and company-wide performance," Welman said.

Separately, the firm announced a new £5m working capital loan drawdown facility from 29% stakeholder, PhillipCapital, providing it with necessary funding to "support its future plans and reinforce the company's financial stability". The facility has a fixed term of two years at an interest rate of 9.07% per annum.

"The availability of this loan is instrumental, without it, the group would lack the capacity to implement essential changes and invest in the growth strategies required to move our business forward," Welman said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.